Five Prime Founder Rusty Williams Returns With Walking Fish Therapeutics
Focusing On B-Cell Therapies
Executive Summary
Named after a remarkable self-regenerating salamander, the new San Francisco biotech aims to unlock the potential of B-cells to be “in vivo protein factories”.
You may also be interested in...
Finance Watch: Kallyope Leads Latest Group Of VC Mega-Rounds With $236m Raise
Private Company Edition: In other $100m-plus venture capital rounds, Third Harmonic Bio emerged with $155m, including a new $105m series B round. Also, Europe- and Japan-focused Newton Biocapital launched its second VC fund with €50m in initial capital and a €150m fundraising goal.
Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.